listing plans and opt for Hong Kong instead, with one source at the time citing Beijing's concerns that U.S. regulators will potentially gain more access to audit documents of New York-listed Chinese companies. read moreĪnalysts also note the tougher stance coincides with new U.S. regulations being rolled out that could see Chinese companies delisted if they do not comply with U.S. auditing rules.Read more: Didi Hit With U.S. LinkDoc’s IPO delay also comes as regulators in Beijing are planning rule changes that would allow them to block a Chinese company from listing overseas even if the unit selling shares is incorporated outside China, closing a loophole long-used by the country’s technology giants, Bloomberg News reported this week. Reuters reported LinkDoc’s IPO halt earlier Thursday. A representative for LinkDoc declined to comment. LinkDoc, founded in 2014, provides cancer focused health-care services built on big data and artificial intelligence, its website shows.
Its investors include Alibaba Health Information Technology Ltd., MBK Partners, New Enterprise Associates and Temasek Holdings Pte according to a preliminary filing.Ĭhinese companies have raised about $13 billion through first-time share sales in the U.S. This year, according to data compiled by Bloomberg.
0 kommentar(er)
